Omerovic E, Ramunddal T, Petursson P, Angeras O, Rawshani A, Jha S
Eur Heart J. 2024; 46(6):518-531.
PMID: 39601339
PMC: 11804248.
DOI: 10.1093/eurheartj/ehae700.
Park S, Kim B
J Liver Cancer. 2023; 20(1):25-31.
PMID: 37383054
PMC: 10035704.
DOI: 10.17998/jlc.20.1.25.
Ahn J, Lee Y, Agopian V, Zhu Y, You S, Tseng H
Hepatoma Res. 2022; 8.
PMID: 36161213
PMC: 9499372.
DOI: 10.20517/2394-5079.2021.131.
Torres M, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M
Cancers (Basel). 2020; 12(6).
PMID: 32486355
PMC: 7352281.
DOI: 10.3390/cancers12061422.
Hanouneh I, Alkhouri N, Singal A
Clin Mol Hepatol. 2019; 25(3):264-269.
PMID: 30827081
PMC: 6759429.
DOI: 10.3350/cmh.2019.1001.
Management of hepatocellular carcinoma.
Fitzmorris P, Shoreibah M, Anand B, Singal A
J Cancer Res Clin Oncol. 2014; 141(5):861-76.
PMID: 25158999
DOI: 10.1007/s00432-014-1806-0.
Optimal management of colorectal liver metastases in older patients: a decision analysis.
Yang S, Alibhai S, Kennedy E, El-Sedfy A, Dixon M, Coburn N
HPB (Oxford). 2014; 16(11):1031-42.
PMID: 24961482
PMC: 4487755.
DOI: 10.1111/hpb.12292.
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish R, Finn R, Marrero J
Gastroenterol Hepatol (N Y). 2014; 9(4 Suppl 2):1-24.
PMID: 24872793
PMC: 4030702.
A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events.
Lytsy P, Berglund L, Sundstrom J
Eur J Epidemiol. 2012; 27(12):903-9.
PMID: 23224516
PMC: 3539066.
DOI: 10.1007/s10654-012-9752-0.
From liver cirrhosis to HCC.
Bolondi L, Gramantieri L
Intern Emerg Med. 2011; 6 Suppl 1:93-8.
PMID: 22009618
DOI: 10.1007/s11739-011-0682-8.
Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey.
Dahl R, Gyrd-Hansen D, Kristiansen I, Nexoe J, Nielsen J
BMC Med Inform Decis Mak. 2007; 7:8.
PMID: 17394656
PMC: 1851704.
DOI: 10.1186/1472-6947-7-8.
Treatment of high blood pressure and gain in event-free life expectancy.
Kassai B, Boissel J, Cucherat M, Boutitie F, Gueyffier F
Vasc Health Risk Manag. 2007; 1(2):163-9.
PMID: 17315403
PMC: 1993937.
DOI: 10.2147/vhrm.1.2.163.64086.
Educating health professionals about drug and device promotion: advocates' recommendations.
Mansfield P, Lexchin J, Wen L, Grandori L, McCoy C, Hoffman J
PLoS Med. 2006; 3(11):e451.
PMID: 17090212
PMC: 1630716.
DOI: 10.1371/journal.pmed.0030451.
Assessing heart disease risk in primary care. Cholesterol lowering should be just one part of a multiple risk factor intervention.
Fahey T
BMJ. 1998; 317(7166):1093-4.
PMID: 9784437
PMC: 1114101.
DOI: 10.1136/bmj.317.7166.1093.
Prostate cancer: 2. Natural history.
Nam R, Jewett M, Krahn M
CMAJ. 1998; 159(6):685-91.
PMID: 9780970
PMC: 1229700.